Zavondemstat
Based on 1 publication(s) in Google Scholar
Zavondemstat (QC8222 free base; TACH 101 free base) is an orally active pan-KDM4 and DHODH inhibitor. Zavondemstat inhibits KDM4A, KDM4B, KDM4C and KDM4D with IC50 values ≤0.080 µM, and exhibits an IC50 of 0.6 nM against human DHODH. Zavondemstat inhibits the KDM4C histone demethylase by competing with the α-ketoglutarate cofactor, and targets DHODH in de novo pyrimidine biosynthesis. Zavondemstat induces apoptosis and S-phase cell cycle arrest, reduces the tumor-initiating cell population, and shows broad antiproliferative activity across multiple cancer cell lines and donor-derived organoids. Zavondemstat can be used for research on colorectal cancer, esophageal squamous cell carcinoma, triple-negative breast cancer and glioblastoma.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.29%
- CAS. Nr.: 1851412-93-5
- Formel: C26H29N3O3
- Molecular Weight:431.53
-
Speicherung:
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications Citing Use of MedChemExpress (MCE) Zavondemstat
More
Biologische Aktivität
Beschreibung
|
DHODH 0.6 nM (IC50) |
KDM4A ≤ 0.08 μM (IC50) |
KDM4B ≤ 0.08 μM (IC50) |
KDM4C ≤ 0.08 μM (IC50) |
KDM4D ≤ 0.08 μM (IC50) |
KDM4A 0.52 μM (Ki) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| KYSE-150 cell line | IC50 |
0.0004 μM
|
Inhibition of endogenous H3K36me3 demethylation in KYSE-150 cells stably overexpressing KDM4C incubated 24 hrs by HTRF assay.
Inhibition of endogenous H3K36me3 demethylation in KYSE-150 cells stably overexpressing KDM4C incubated 24 hrs by HTRF assay.
|
37067993 |
| KYSE-150 cell line | IC50 |
0.085 μM
|
Inhibition of endogenous H3K36me3 demethylation in KYSE-150 cells stably overexpressing KDM4C incubated 24 hrs by immunoblotting.
Inhibition of endogenous H3K36me3 demethylation in KYSE-150 cells stably overexpressing KDM4C incubated 24 hrs by immunoblotting.
|
37067993 |
| Jurkat | IC50 |
0.0027 μM
|
Antiproliferative activity against human Jurkat cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay.
Antiproliferative activity against human Jurkat cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay.
|
37067993 |
| MDA-MB-231 | IC50 |
0.0035 μM
|
Antiproliferative activity against human MDA-MB-231 cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay.
Antiproliferative activity against human MDA-MB-231 cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay.
|
37067993 |
| KYSE-150 cell line | IC50 |
0.0053 μM
|
Antiproliferative activity against human KYSE-150 cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay.
Antiproliferative activity against human KYSE-150 cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay.
|
37067993 |
| MM1.S | IC50 |
0.0090 μM
|
Antiproliferative activity against human MM.1s cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay.
Antiproliferative activity against human MM.1s cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay.
|
37067993 |
| HL-60 | IC50 |
0.0130 μM
|
Antiproliferative activity against human HL-60 cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay.
Antiproliferative activity against human HL-60 cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay.
|
37067993 |
| HT-29 | IC50 |
0.0235 μM
|
Antiproliferative activity against human HT-29 cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay.
Antiproliferative activity against human HT-29 cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay.
|
37067993 |
| MCF7 | IC50 |
0.0370 μM
|
Antiproliferative activity against human MCF-7 cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay.
Antiproliferative activity against human MCF-7 cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay.
|
37067993 |
| LOUCY | IC50 |
0.01 μM
|
Antiproliferative activity against human Loucy cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay; IC50 <0.01 μM.
Antiproliferative activity against human Loucy cells assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay; IC50 <0.01 μM.
|
37067993 |
| IMR-90 | IC50 |
1.0 μM
|
Cytotoxicity against normal human IMR-90 fibroblasts assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay; IC50 >1.0 μM.
Cytotoxicity against normal human IMR-90 fibroblasts assessed as viability reduction incubated 168 hrs by BrdU ELISA, CellTiter-Glo, or MTS assay; IC50 >1.0 μM.
|
37067993 |
| KYSE-150 cell line | EC50 |
0.033 μM
|
Induction of caspase-3/7 apoptosis in human KYSE-150 cells incubated 72 hrs by luminescent DEVD substrate assay.
Induction of caspase-3/7 apoptosis in human KYSE-150 cells incubated 72 hrs by luminescent DEVD substrate assay.
|
37067993 |
| MDA-MB-231 | EC50 |
0.132 μM
|
Induction of caspase-3/7 apoptosis in human MDA-MB-231 cells incubated 72 hrs by luminescent DEVD substrate assay.
Induction of caspase-3/7 apoptosis in human MDA-MB-231 cells incubated 72 hrs by luminescent DEVD substrate assay.
|
37067993 |
| HT-29 | EC50 |
0.092 μM
|
Induction of caspase-3/7 apoptosis in human HT-29 cells incubated 72 hrs by luminescent DEVD substrate assay.
Induction of caspase-3/7 apoptosis in human HT-29 cells incubated 72 hrs by luminescent DEVD substrate assay.
|
37067993 |
| HCC1937 | EC50 |
100 μM
|
Induction of caspase-3/7 apoptosis in human HCC1937 cells incubated 72 hrs by luminescent DEVD substrate assay; EC50 >100 μM.
Induction of caspase-3/7 apoptosis in human HCC1937 cells incubated 72 hrs by luminescent DEVD substrate assay; EC50 >100 μM.
|
37067993 |
In Vitro
Zavondemstat (10-0.0005 µM; 7 days) shows broad but selective antiproliferative activity across a 301-cell-line panel, with 209 lines inhibited at IC50 <1 µM[1].
Zavondemstat (144-168 h) is active in SU60, T002C, and SU62 colorectal organoids (IC50 <0.15 µM) and PA0165F pancreatic organoids (IC50 <0.03 µM), but not in several other organoid models[1].
Zavondemstat (5 days) potently inhibits growth of HW1, FPW1, MMK1 and RKI1 glioblastoma stem cells, with GR50 values of 4, 0.4, 7 and 9 nM, respectively[2].
Zavondemstat (100 μM uridine-5 days) growth inhibition in FPW1 glioblastoma cells is strongly rescued by expression of DHODH A58T, supporting DHODH as the functional target[2].
Zavondemstat (60 min preincubation) selectively inhibits KDM4A-D with IC50 ≤ 0.080 µM and has substantially weaker activity against other KDM families[1].
Zavondemstat (24 h) potently inhibits endogenous H3K36me3 demethylation in KYSE-150+KDM4C cells with HTRF IC50 0.0004 µM[1].
Zavondemstat (0.0001-6.7 µM; 24 h) inhibits endogenous H3K36me3 demethylation in KYSE-150+KDM4C cells by immunoblot with IC50 0.085 µM[1].
Zavondemstat (15 min preincubation-45 min reaction) inhibits recombinant KDM4A with an IC50 of 767 nM[2].
Zavondemstat (30 min preincubation-4 h assay) potently inhibits recombinant DHODH with an IC50 of 0.6 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:KYSE-150 cells overexpressing KDM4C
-
Concentration:0.0001, 0.001, 0.003, 0.009, 0.027, 0.082, 0.25, 2.2, and 6.7 µM
-
Incubation Time:24 h
-
Result:Inhibited H3K36me3 demethylation with a mean IC50 of 0.085 µM.
-
Cell Line:301 cancer cell lines from 24 hematologic and solid cancer types
-
Concentration:10-0.0005 µM (10 doses, 1:3 serial dilution)
-
Incubation Time:7 days
-
Result:IC50 values ranged from <500 pM to >10 µM.
Of 301 cell lines, 209 were inhibited with IC50 <1 µM, 89 were insensitive with IC50 ≥10 µM, and 3 had IC50 between 1 and 10 µM.
-
Cell Line:MDA-MB-231 triple-negative breast cancer cells
-
Concentration:0.01 and 0.1 µM
-
Incubation Time:24 h (S-phase data); 48 or 72 h (Methods)
-
Result:Caused S-phase accumulation: 33% and 40% of cells were in S-phase after 0.01 and 0.1 µM, respectively.
Longer exposure resulted in more cells arrested in S-phase.
-
Cell Line:FPW1 and RKI1 glioblastoma cells
-
Concentration:100 μM (uridine)
-
Incubation Time:5 days; 90 min (fluorescence)
-
Result:Exogenous uridine fully reversed growth inhibition in FPW1 and RKI1 glioblastoma cells.
-
Cell Line:FPW1 and FPW1-DHODH A58T glioblastoma cells
-
Concentration:100 μM (uridine)
-
Incubation Time:5 days
-
Result:Expression of DHODH A58T strongly rescued antiproliferative efficacy in FPW1 cells.
Residual weak activity at doses >1 μM was reversed by exogenous uridine.
In Vivo
Zavondemstat (10-23 mg/kg; PO; QD ×7 per week; QOD; 3 on/4 off; 5 on/2 off) inhibits SU60 colorectal cancer xenograft growth in a dose-dependent manner, with 71% tumor growth inhibition at 20 mg/kg PO QD ×7 per week[1].
Zavondemstat (12.5-50 mg/kg; PO; QD; 36 days) inhibits COH70 triple-negative breast cancer xenograft growth dose-dependently, reaching 86% tumor growth inhibition at 40 and 50 mg/kg PO QD ×36[1].
Zavondemstat (5-50 mg/kg; PO; 3 on/4 off; 2 on/5 off) inhibits GXA-3036 gastric cancer xenograft growth, with 69% tumor growth inhibition at 15 mg/kg PO on a 3 on/4 off schedule[1].
Zavondemstat (10-20 mg/kg; PO; QD; 21 days) inhibits KYSE-150 esophageal squamous cell carcinoma xenograft growth dose-dependently, with 84% tumor growth inhibition at 20 mg/kg PO QD ×21[1].
Zavondemstat (5-50 mg/kg; PO; QD 3 on/4 off; BID 3 on/4 off) inhibits OCI-LY19 diffuse large B-cell lymphoma xenograft growth dose-dependently, with 102% tumor growth inhibition and three of eight complete regressions at 25 mg/kg PO BID on 3 on/4 off[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG (nonobese diabetic/severe combined immunodeficiency gamma; female)[1]
-
Dosage:40 mg/kg
-
Administration:PO; QD; 21 days
-
Result:Reduced the proportion of tumorigenic CD44^High EpCAM^+ cells by 2.5-fold and reduced tumor-initiating cell frequency by 4.4-fold.
In limiting dilution, tumor take rates were 7/10 at 1000 cells (mean tumor volume 830 mm3), 5/10 at 500 cells (589 mm3), and 3/10 at 50 cells (209 mm3); TIC frequency was 1 in 643 cells.
-
Animal Model:NSG mice[1]
-
Dosage:5 mg/kg (3 on/4 off); 15 mg/kg (3 on/4 off); 50 mg/kg (3 on/4 off); 22.5 mg/kg (2 on/5 off)
-
Administration:PO; 3 on/4 off; 2 on/5 off
-
Result:On the 3 on/4 off schedule, tumor growth inhibition was 43% at 5 mg/kg, 69% at 15 mg/kg, and 52% at 50 mg/kg.
At 22.5 mg/kg on the 2 on/5 off schedule, TGI was 41%.
-
Animal Model:NSG mice[1]
-
Dosage:10 mg/kg; 15 mg/kg; 20 mg/kg
-
Administration:PO; QD; 21 days
-
Result:Produced dose-dependent tumor growth inhibition of 54% at 10 mg/kg, 76% at 15 mg/kg, and 84% at 20 mg/kg.
-
Animal Model:NSG mice[1]
-
Dosage:5 mg/kg (QD 3 on/4 off); 15 mg/kg (QD 3 on/4 off); 50 mg/kg (QD 3 on/4 off); 25 mg/kg (BID 3 on/4 off)
-
Administration:PO; QD 3 on/4 off; BID 3 on/4 off
-
Result:Produced dose-dependent tumor growth inhibition of 55% at 5 mg/kg, 83% at 15 mg/kg, and 90% at 50 mg/kg on the QD 3 on/4 off schedule.
At 25 mg/kg BID on 3 on/4 off, TGI was 102%, with three of eight complete regressions.
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Flow cytometric DNA-content cell-cycle staining
- Annexin V plus membrane-impermeant dye apoptosis staining
- BrdU Incorporation Assay
- Apoptosis Solutions
- Protocol for Cell Cycle
- Breast Cancer Modeling
- Cell Viability Determination by MTT Colorimetric Assay
Chemical Information
-
CAS. Nr. 1851412-93-5
-
Appearance Solid
-
Molecular Weight 431.53
-
Formel C26H29N3O3
-
Color Light yellow to yellow
-
SMILES
OC(C1=CC=NC=C1NC[C@H]2C3=CC=C(N(C4=CC=C(C=C4)C(C)C)C)C=C3OCC2)=O
-
Synonyms
QC8222 free base; TACH 101 free base
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Lösungsmittel & Löslichkeit
In Vitro:
DMF : 10 mg/mL (23.17 mM; Need ultrasonic)
DMSO : 4.17 mg/mL (9.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMF 90% Corn Oil
Solubility: ≥ 1 mg/mL (2.32 mM); Clear solution
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (287 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / DMF | 1 mM | 2.3173 mL | 11.5867 mL | 23.1734 mL | 57.9334 mL |
| 5 mM | 0.4635 mL | 2.3173 mL | 4.6347 mL | 11.5867 mL | |
| DMF | 10 mM | 0.2317 mL | 1.1587 mL | 2.3173 mL | 5.7933 mL |
| 15 mM | 0.1545 mL | 0.7724 mL | 1.5449 mL | 3.8622 mL | |
| 20 mM | 0.1159 mL | 0.5793 mL | 1.1587 mL | 2.8967 mL |
Keywords
- Zavondemstat
- 1851412-93-5
- QC8222
- TACH 101
- QC 8222
- QC-8222
- TACH101
- TACH-101
- Histone Demethylase
- Apoptosis
- Dihydroorotate Dehydrogenase
- DHODH
- KDM4 histone demethylase
- S-phase cell cycle arrest
- alpha-ketoglutarate
- apoptosis
- colorectal cancer
- de novo pyrimidine biosynthesis
- glioblastoma
- tumor-initiating cell
- xenograft
- Inhibitor
- inhibitor
- inhibit